Journal section: Oral Surgery Publication Types: Review

doi:10.4317/medoral.26788

# Certainty of evidence on the effects of cryotherapy, surgical wound closure, and chlorhexidine on clinical and patient-centered outcomes after third molar surgery: evidence mapping of systematic reviews and meta-analyses

Edmundo Marques do Nascimento-Júnior<sup>1,2</sup>, Fábio Wildson Gurgel Costa<sup>3</sup>, Paulo Ricardo Martins-Filho<sup>1,2,4</sup>

<sup>3</sup> Division of Oral and Maxillofacial Surgery, Graduate Program in Dentistry, Federal University of Ceará, Fortaleza, CE, Brazil

Correspondence:

Universidade Federal de Sergipe Hospital Universitário, Laboratório de Patologia Investigativa Rua Cláudio Batista, s/n. Bairro Sanatório CEP: 49060-100, Aracaju, Sergipe, Brasil prmartinsfh@gmail.com

Received: 01/07/2024 Accepted: 17/01/2025 Please cite this article in press as: Nascimento-Júnior EM, Costa FW, Martins-Filho PR. Certainty of evidence on the effects of cryotherapy, surgical wound closure, and chlorhexidine on clinical and patient-centered outcomes after third molar surgery: evidence mapping of systematic reviews and meta-analyses. Med Oral Patol Oral Cir Bucal. 2025. doi:10.4317/medoral.26788

## Abstract

Background: Removal of third molars often leads to complications such as pain, swelling, and trismus, impacting patient quality of life. Various strategies including cryotherapy, different suture techniques, and chlorhexidine are employed to mitigate these effects. However, the effectiveness of these interventions is still debated, as clinical trials present inconsistent and contrasting results. This study aims to assess the certainty of evidence from systematic reviews and meta-analyses regarding the effects of these interventions on clinical outcomes and patient quality of life following third molar surgery.

Material and Methods: This evidence mapping followed the Global Evidence Mapping Initiative and PRISMA guidelines, utilizing databases such as PubMed, Embase, Cochrane, Web of Science, and Google Scholar until February 2024. Methodological quality was assessed via AMSTAR-2 and the effects of these interventions on outcomes of interest were classified as "beneficial", "probably beneficial", "harmful", "no effect", or "inconclusive". Findings were mapped using the PyMeta platform.

Results: Thirteen studies were reviewed. All systematic reviews evaluated the effects of these interventions on clinical outcomes following third molar surgery, but none assessed the impact on patient quality of life. Cryo-therapy was classified as probably beneficial for reducing pain and swelling within the first 72 hours post-surgery. Secondary surgical wound closure was effective in reducing pain, swelling, and trismus during the first postopera-tive week, but it did not mitigate the risk of bleeding, infection, or alveolitis. Chlorhexidine, especially when used as a mouthwash, is effective in preventing postoperative alveolitis. However, most reviews (76.9%) were rated as "critically low" methodological quality.

Conclusions: Although the potential benefits of cryotherapy, secondary surgical wound closure, and chlorhexidine on clinical outcomes, this study revealed a predominantly low quality of evidence from systematic reviews and meta-analyses. Moreover, further research should expand investigations into the patient-centered outcomes to better guide clinical practice.

<sup>&</sup>lt;sup>1</sup> Graduate Program in Dentistry, Federal University of Sergipe, Aracaju, SE, Brazil

<sup>&</sup>lt;sup>2</sup> Investigative Pathology Laboratory, Federal University of Sergipe, Aracaju, SE, Brazil

<sup>&</sup>lt;sup>4</sup> Graduate Program in Health Sciences, Federal University of Sergipe, Aracaju, SE, Brazil

*Key words: Third molar, oral surgery, postoperative complications, pain, edema, cryotherapy, suture techniques, chlorhexidine, evidence-based dentistry.* 

## Introduction

The extraction of third molars is a common dental procedure, often indicated due to complications such as impaction or misalignment (1,2). Despite its routine nature, this procedure can lead to several postoperative complications, including pain, swelling, trismus, alveolitis, and infections (3,4), significantly affecting patient's daily activities and overall well-being (5). To mitigate these adverse outcomes, various preventive and therapeutic strategies are employed in clinical practice, such as cryotherapy (4,6), diverse wound closure techniques (7,8), and the use of antiseptics like chlorhexidine (9,10). However, the efficacy of these interventions remains a topic of debate in the literature, with some clinical trials reporting modest or inconclusive results, while others demonstrate significant improvements in postoperative outcomes (7,11). This inconsistency underscores the need for comprehensive and systematic evaluations of the existing evidence. Systematic reviews and metaanalyses address this need by synthesizing data from multiple studies and critically assessing the certainty of available evidence, thereby providing more reliable conclusions regarding the effectiveness of these interventions.

This study aims to assess the certainty of evidence from systematic reviews and meta-analyses regarding the effects of cryotherapy, surgical wound closure, and chlorhexidine on clinical outcomes and quality of life in patients undergoing third molar surgery. Through this evidence mapping, we aim to identify and address existing gaps in the literature, thereby informing future research and optimizing outcomes following third molar extractions.

## **Material and Methods**

We conducted an evidence mapping according to the Global Evidence Mapping Initiative methodology (12) and adhered to the PRISMA Extension for Scoping Reviews (13) (Supplement 1). Our approach also included an assessment of the methodological quality of the reviews included (14). The protocol for our study was registered a priori on the Open Science Framework platform (https://doi.org/10.17605/OSF.IO/DAST9).

## - Research question

This evidence mapping was conducted to address the following research question: "What is the certainty of the available evidence regarding the effects of cryo-therapy, surgical wound closure, and chlorhexidine on clinical outcomes and quality of life after third molar surgery?"

### - Eligibility criteria

We included systematic reviews regardless of publication year or language. These reviews must focus on evaluating the effectiveness of cryotherapy, surgical wound closure techniques, and the use of chlorhexidine in managing postoperative complications following third molar extractions. Each systematic review had to report at least one of the following outcomes: pain, swelling, trismus, bleeding, surgical wound infection, or alveolitis. Additionally, we sought to identify reviews that assessed the impact of these complications on the quality of life of patients undergoing these procedures. In cases of updated systematic reviews, both studies were retained, as many reviews improve their methodology and address limitations over time. Systematic reviews without meta-analysis, overview-type studies, and network meta-analyses were excluded.

## - Search strategy

We conducted a systematic search in four databases (PubMed, Embase, Cochrane, and Web of Science) in September 2023, with an update in February 2024, to identify systematic reviews and meta-analyses relevant to our study. Additionally, we evaluated the top 100 search results on Google Scholar. Our search strategy used a comprehensive approach, incorporating Medical Subject Headings (MeSH) and Entry Terms (EM-TREE), along with specific keywords related to our topics of interest, including variations such as: "Third molar", "Third molars", "Wisdom tooth", "Wisdom teeth", "Cryotherapy", "Cold therapy", "Ice", "Suture", "Sutures", "Suture technique", "Suture techniques", "Closure technique", "Closure techniques", "Closure ways", "Primary closure", "Secondary closure", "Wound closure", "Wound healing", "Surgical wound", and "Chlorhexidine".

To ensure thorough coverage, we tailored the search strategy for each database. Additionally, we performed a manual search through the reference lists of the included systematic reviews to identify any relevant studies might have been overlooked during the electronic database searches. We conducted separate searches for each intervention of interest—cryotherapy, surgical wound closure techniques, and chlorhexidine—to guarantee thorough and pertinent results for each intervention. Detailed search strategies for each database are outlined in the Supplement 2, providing transparency and facilitating the reproducibility of our search methodology for future research.

- Selection of systematic reviews

We managed all retrieved titles and abstracts using the

Ryyan platform (available at https://www.rayyan.ai/). After removing duplicates, two reviewers (EMNJ and PRMF) independently screened all titles and abstracts for potentially relevant studies. Subsequently, potentially eligible articles were set aside for full-text reading and decision-making. Discrepancies were resolved by consensus or consultation with a third reviewer (JWGC). Detailed explanations were provided for the exclusion of any study after full-text review.

- Methodological quality assessment of systematic reviews We evaluated the methodological quality of each included systematic review using the AMSTAR-2 tool (15). This validated instrument consists of 16 items specifically designed to critically assess the quality of systematic reviews. The overall rating is derived from identified weaknesses in key domains, notably items 2, 4, 7, 9, 11, 13, and 15. Confidence in the review outcomes is classified into four levels: "High", indicating no or only one non-critical weakness; "Moderate", indicating the presence of more than one non-critical weakness; "Low", applicable when there is one critical flaw, with or without additional non-critical weaknesses; and "Critically Low", applicable when multiple critical flaws are present, with or without non-critical weaknesses.

Two researchers (EMNJ and PRMF) independently conducted the methodological quality assessments using the tool's online checklist (https://amstar.ca/ Amstar\_Checklist.php). Following the discussion of individual findings, we compiled a table detailing the quality of evidence rating for each review. If a review was authored by one of the researchers responsible for this phase, a third reviewer (EMNJ and PRMF) was appointed for the assessment.

- Data extraction

Data extraction was also performed by two researchers (EMNJ and PRMF), independently, using a pre-formatted Excel spreadsheet. Discrepancies were resolved by consensus or consultation with a third reviewer (EMNJ and PRMF). The following information was extracted from the selected systematic reviews:

1. Authors, country, and year of publication.

- 2. Number of clinical trials included.
- 3. Population.

4. Interventions: cryotherapy, surgical wound closure, or chlorhexidine.

- 5. Comparisons.
- a. For cryotherapy: non-use of ice.

b. Surgical wound closure: primary closure with suture versus secondary closure.

c. For chlorhexidine: placebo, any other substance used for the same purpose, or no treatment.

6. Outcomes of interest:

a. For cryotherapy: pain, swelling, trismus, and quality of life.

b. For wound closure: pain, swelling, trismus, bleeding,

surgical wound infection, alveolitis, and quality of life. c. For chlorhexidine: surgical wound infection, alveolitis, and quality of life.

7. Tool used for risk of bias assessment.

8. Assessment of evidence certainty through the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) (16).

- Effects of interventions on outcomes of interest

The impacts of the interventions on the outcomes of interest were evaluated primarily through findings from meta-analyses, with a particular focus on forest plots. This analysis extended beyond mere summary measures; it also examined the direction and confidence intervals of the effects observed in individual studies included in each meta-analysis. Such a comprehensive approach enables a detailed interpretation of results, enhancing our understanding of the effect magnitude of the assessed interventions.

The effects of cryotherapy, surgical wound closure, and chlorhexidine in the postoperative period after third molar removal were classified as: 1) "Beneficial": when the summary measure demonstrated a significant reduction in postoperative complications, supported by confidence intervals from individual studies that mostly did not cross the null line, indicating a clear improvement in the outcomes of interest; 2) "Probably beneficial": when the summary measure showed a reduction in postoperative complications, although with confidence intervals from individual studies approaching the null line. Such results indicated a possible advantage of the interventions, requiring, however, more evidence for a definitive conclusion; 3) "Harmful": interventions were considered harmful when the summarized results pointed to a significant increase in postoperative complications compared to the comparison group; 4) "No effect": this classification was applied when the summary measure did not demonstrate a significant difference in postoperative complications between compared groups; 5) "Inconclusive": assigned to interventions whose results did not allow for a clear interpretation due to limitations such as wide confidence intervals, insufficient studies, or significant variability in the results of the studies. This category reflects the need for additional research to clarify the effect of the interventions.

- Presentation of evidence mappings

We displayed the evidence mappings using bubble charts, where each bubble corresponds to a systematic review. These charts provide information in three dimensions: 1) the classification of the effects of the interventions represented on the X-axis; 2) the AMSTAR-2 assessment on the Y-axis; and 3) the author, year, and size of the population included in each systematic review above each bubble, with the size of the bubble proportional to the size of the population. Additionally, we also presented tables describing the characteristics of

the studies shown in the bubble charts, including information about authors, follow-up period, measure, and effect. The figures were generated using the PyMeta platform (https://www.pymeta.com/evdmap/).

## Results

## - Selected studies

The database search resulted in 520 records, including 114 for cryotherapy, 242 for surgical wound closure methods, and 164 for chlorhexidine. Following the initial screening based on titles and abstracts, 17 studies were selected for full-text review (three related to cryotherapy, six to wound closure, and eight to chlorhexidine. Out of these, 13 systematic reviews (two on cryotherapy, five on wound closure, and six on chlorhexidine) (17-29) met the eligibility criteria. The search and selection process are thoroughly detailed in Fig. 1 list of excluded studies, with the reasons for their exclusion, is provided in the Supplement 3.

## - Characteristics of included systematic reviews

All included systematic reviews conducted meta-analyses for at least one of the evaluated outcomes and were published in English from 2005 to 2024. Two reviews (17,18) specifically focused on the effects of cryotherapy, four (19,21-23) exclusively on surgical wound closure methods, and five (24-27,29) on the use of chlorhexidine. One review (28) examined various interventions for alveolitis, though data pertaining only to chlorhexidine were extracted for this study. Another review (20) investigated multiple interventions and their impacts on various outcomes; however, we extracted data related to wound closure.

All studies investigating cryotherapy evaluated edema and trismus, but only one (18) assessed pain. In the case of surgical wound closure, all studies assessed pain, edema, and trismus; four studies additionally explored bleeding (19-21,23), and three surgical wound infection and alveolitis (19-21). As for the studies on chlorhexidine, all systematically reviewed alveolitis. None of the studies across these interventions reported data on quality of life.

The number of clinical trials included in each review varied from 4 to 40. Twelve reviews used a tool to assess the quality of primary studies, with eleven using the Cochrane Collaboration tool (17-23,26-29) and one using the Macaskill, Gleser-Olkin, and Rosenthal method (25) Only six reviews applied the GRADE methodology (18-21,23,28) to assess the quality of evidence from individual studies. Table 1 presents the general characteristics of the included systematic reviews.




Fig. 1: PRISMA flowchart detailing the selection process.

	Author	Trials	Intervention	n vs. Control	Outcomes of interest	
	(year)		Comparison Time		Outcomes of interest	
Cryo-	Fernandes (2019)	4	Ice pack vs. no use of ice	Immediately and for 24h post-surgery	Edema and trismus	
therapy	Nascimento-Júnior (2019)	6	Ice pack vs. no use of ice	Immediately and for 24h post-surgery	Pain, edema, and trismus	
	Carrasco-Labra (2012)	14	Secondary vs. primary closure	Immediately after surgery	Pain, edema, trismus, bleeding, wound infection, and alveolitis	
	Ma (2019)	5	Secondary vs. primary closure	Immediately after surgery	Pain, edema, and trismus	
Wound	Bailey (2020)	8	Secondary vs. primary closure	Immediately after surgery	Pain, edema, trismus, bleeding, wound infection, and alveolitis	
	Azab (2022)	40	Secondary <i>vs.</i> primary closure	Immediately after surgery	Pain, edema, trismus, bleeding, wound infection, and alveolitis	
	Falci (2024)	7	Secondary vs. primary closure	Immediately after surgery	Pain, edema, trismus, and bleeding	
	Caso (2005)	7	CHX rinse vs. placebo or others*	Pre- and post- surgery	Alveolitis	
	Rodríguez-Sánchez (2017)	18	CHX rinse and gel vs. placebo or others*	Rinse: pre- and post- surgery. Gel: intra- socket	Alveolitis	
Chlorhex-	Zhou (2017)	11	CHX gel vs. placebo or others*	Not specified	Alveolitis	
idine	Teshome (2017)	10	CHX gel <i>vs.</i> placebo or others*	Not specified	Alveolitis	
	Daly (2022)	15	CHX rinse and gel vs. placebo or others*	Rinse: before and 24h post-surgery. Gel: intra-socket	Alveolitis	
	Romero-Olid (2023)	33	CHX rinse and gel vs. placebo or others*	Not specified	Alveolitis	

Table 1: Characteristics of the meta-analyses included in the evidence mapping.

CHX, chlorhexidine. \*Others: Saline solution, dressings, or no treatment.

- Methodological quality of systematic reviews

Ten systematic reviews (17-19,21-27) were rated as "critically low", one (29) as "moderate", and only two (20,28) as "high" methodological quality, according to the AM-STAR-2 criteria. Most reviews were downgraded for not referencing a protocol (nine studies; 69.2%) and for not providing a list of excluded studies (eight studies; 61.5%). All information regarding the application of AMSTAR-2 is detailed in Fig. 2.

- Evidence mapping and effects of interventions of interest

The evidence mapping on cryotherapy, surgical wound closure type, and the use of chlorhexidine in reducing pain, swelling, and trismus, and in preventing bleeding, infection, and alveolitis after third molar removal surgery revealed 66 analyses on the effects of these interventions across various controls and outcomes.

#### - Cryotherapy

Two systematic reviews (17,18) evaluated the effectiveness of cryotherapy in reducing pain, swelling, and trismus. Cryotherapy was deemed "probably beneficial" for reducing pain on the second and third postoperative days, as well as for diminishing swelling on the second postoperative day. However, the quality of the studies that provided these findings was rated as "critically low" according to AMSTAR-2 criteria. There is no evidence to support the effectiveness of cryotherapy in alleviating pain on the first- and seventh-days postsurgery, reducing swelling from the third postoperative day, or in attenuating trismus at any later stage following the surgical procedure. All information extracted regarding the effects of cryotherapy is detailed in Table 2 and a bubble chart displaying these results is available in Fig. 3.

Autho	or Cryo	therapy	Wound closure			Chlorhexidine							
	Fernandes	Nascimento-	Carrasco-	Ma	Bailey	Azab	Falci	Caso	Rodríguez-	Teshome	Zhou	Daly	Romero-Olid
Question	2019	Júnior 2019	Labra 2012	2019	2020	2022	2024	2005	Sánchez	2017	2017	2022	2023
									2017				
1	•	•	•	•	•	•	•	•	•	•	•	•	•
2	٠	•	٠	•	•	٠	•	٠	٠	•	٠	•	•
3	•	•	٠	٠	٠	•	•	•	•	•	٠	•	•
4	•	•	•	•	•	٠	•	•	•	•	•	•	•
5	•	•	•	•	•	•	•	•	•	•	•	•	•
6	•	•	•	•	٠	٠	•	٠	•	•	•	•	•
7	•	•	•	•	•	٠	•	•	•	•	٠	•	•
8	•	•	•	•	٠	٠	٠	٠	•	•	•	•	•
9	•	•	•	•	•	•	•	•	•	•	•	•	•
10	•	•	•	٠	٠	•	•	٠	•	•	•	•	•
11	•	•	•	•	•	•	•	•	•	•	•	•	•
12	•	•	٠	٠	٠	٠	٠	٠	•	٠	٠	٠	•
13	•	•	•	٠	٠	•	٠	٠	٠	٠	٠	•	٠
14	•	•	•	•	•	•	•	•	•	•	•	٠	•
15	•	•	•	•	•	•	•	•	•	•	•	•	•
16	٠	٠	۲	٠	•	•	•	٠	•	٠	•	٠	•
Score	CLQ	CLQ	CLQ	CLQ	HQ	CLQ	CLQ	CLQ	CLQ	CLQ	CLQ	HQ	MQ

#### ●, Yes; ●, Partial Yes; ●, No.

Questions: 1. Did the research questions and inclusion criteria for the review include the components of PICO? 2. Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review and did the report justify any significant deviations from the protocol? 3. Did the review authors explain their selection of the study designs for inclusion in the review? 4. Did the review authors use a comprehensive literature search strategy? 5. Did the review authors perform data extraction in duplicate? 7. Did the review authors perform data extraction in duplicate? 7. Did the review authors perform data extraction in duplicate? 7. Did the review authors performed a extraction in duplicate? 7. Did the review authors perform data extraction in duplicate? 7. Did the review authors performed a extraction in duplicate? 7. Did the review authors performed a extraction in duplicate? 7. Did the review authors performed and extraction in duplicate? 7. Did the review authors performed and extraction in duplicate? 7. Did the review authors performed a extraction in duplicate? 7. Did the review authors performed a extraction in duplicate? 7. Did the review authors performed a extraction in duplicate? 7. Did the review authors performed a statistical combination of results? 9. Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? 10. Did the review authors report on the sources of funding for the studies included in the review? 11. If meta-analysis was performed did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? 14. Did the review? 13. Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? 14. Did the review? 15. If they performed quantitative synthesis? 14. Did the review authors carry out an adequate investigation of publication bias (small study bias) a


Fig. 2: Assessment of the Methodological Quality of Systematic Reviews (AMSTAR-2) included.

	Author (year)	Sample Size	Follow-up	Measurement	Effect
D :	Nascimento-Junior (2019)	124	POD1	MD 0.17 (-0.67 to 1.01)	No effect
	Nascimento-Junior (2019)	124	POD2	MD -0.72 (-1.45 to -0.01)	Probably beneficial
Pain	Nascimento-Junior (2019)	100	POD3	MD -0.36 (-0.59 to -0.13)	Probably beneficial
	Nascimento-Junior (2019)	160	POD7	MD -0.46 (-1.28 to 0.37)	No effect
	Nascimento-Junior (2019)	88	POD2	SMD -0.28 (-0.88 to 0.31)	No effect
	Nascimento-Junior (2019)	36	POD3	SMD -2.26 (-3.12 to -1.40)	Inconclusive
Edema	Nascimento-Junior (2019)	96	POD7	SMD -0.52 (-1.92 to 0.89)	Inconclusive
	Fernandes (2019)	85	POD2	MD -0.94 (-1.49 to -0.39)	Probably beneficial
	Fernandes (2019)	85	POD7	MD -0.35 (-1.34 to 0.64)	Inconclusive
	Nascimento-Junior (2019)	118	POD1	MD -0.27 (-3.81 to 3.26)	No effect
	Nascimento-Junior (2019)	88	POD2	MD 0.22 (-3.49 to 3.93)	Inconclusive
	Nascimento-Junior (2019)	36	POD3	MD -0.63 (-1.60 to 0.34)	Inconclusive
Trismus	Nascimento-Junior (2019)	186	POD7	MD -0.04 (-0.63 to 0.54)	Inconclusive
	Fernandes (2019)	143	POD1	MD 0.55 (-2.14 to 3.24)	Inconclusive
	Fernandes (2019)	85	POD2	MD 2.37 (-0.50 to 5.24)	No effect
	Fernandes (2019)	203	POD7	MD 0.76 (-3.10 to 4.63)	Inconclusive

Table 2: Synthesis of extracted data on cryotherapy for reduction of pain, edema, and trismus after third molar extraction.

POD1, first postoperative day; POD2, second postoperative day; POD3, third postoperative day; POD7, seventh postoperative day; MD, mean difference; SMD, standardized mean difference.

Negative effect measures for continuous outcomes indicated favorability towards cryotherapy.



PODI, first postoperative day; POD2, second postoperative day; POD3, third postoperative day; POD2-3, between second and third postoperative day; POD5-7, between fifth and seventh postoperative day; POD7, seventh postoperative day.

**Fig. 3:** Evidence mappings on the effects of (A) cryotherapy, (B and C) surgical wound closure, and (D) chlorhexidine on clinical outcomes after third molar surgery.

## - Surgical wound closure

Five systematic reviews (19-23) evaluated the efficacy of secondary closure, compared to primary closure, in reducing pain, swelling, and trismus, and in preventing bleeding, wound infection, and alveolitis. Generally, secondary closure was considered "beneficial" or "probably beneficial" in reducing pain, swelling, and trismus during the first week of postoperative. However, the evidence quality was considered "high" only for reducing pain on the first postoperative day and swelling after seven days of surgery. For other outcomes and evaluation times, the evidence quality was "critically low". No evidence was found supporting the reduction of bleeding, infection, or alveolitis risk with the secondary closure technique. All information extracted about the effects of secondary surgical wound closure is presented in Table 3 and bubbles charts with these results can be seen in Fig. 3. - Chlorhexidine

Six systematic reviews assessed the efficacy of chlorhexidine as a preventive agent for postoperative alveolitis (24-29). The best available evidence characterizes chlorhexidine, especially when used as a mouthwash, as "beneficial" or "probably beneficial" in preventing alveolitis. All information extracted for the effects of chlorhexidine is recorded in Table 4 and a bubble chart with these results can be seen in Fig. 3.

## Discussion

This study represents one of the initial efforts in oral surgery to employ evidence mapping for third molar removal, assessing the certainty of evidence concerning the effects of cryotherapy, surgical wound closure, and chlorhexidine in alleviating common postoperative complications. While not intended to supplant established clinical protocols or guidelines, our analysis provides a thorough and critical synthesis that highlights both the potential advantages and constraints of these interventions. Recommendations arising from our findings should be interpreted within the specific clinical context of each patient, considering alternative approaches, cost-effectiveness, and other pertinent contextual factors.

The results of our evidence mapping indicate a limited and variable quality among systematic reviews assessing the discussed interventions and outcomes. From a total of 520 records found across multiple databases, only 17 systematic reviews were identified and selected for full reading. Of these, only 13 met the inclusion criteria. Although most of the included reviews present a limited number of primary studies, all of them were based on clinical trial data, which is considered the highest level of evidence for evaluating the efficacy of therapeutic interventions (30).

However, the methodological quality of the reviews analyzed varied significantly, with many categorized as "low" or "critically low". This study underscores the prevalence of methodological shortcomings, including the lack of predefined protocols, insufficient justification for including certain study types, and a lack of publication bias assessment. Such deficiencies can undermine the reliability of the results and, consequently, the credibility of clinical recommendations derived from these reviews. Although not a required step in evidence mapping, it is recommended that all types of reviews incorporate a methodological quality assessment to ensure the consistency of their conclusions (14,31).

Despite the essential role of the AMSTAR-2 tool in evaluating the methodological quality of systematic reviews, we recognize its limitations. The AMSTAR-2 scoring system emphasizes critical items, specifically questions 2, 4, 7, 9, 11, 13, and 15, where a single critical flaw can downgrade an otherwise "high-quality review to "low" or "critically low". This approach can result in assessments that do not accurately reflect the robustness of a review. For instance, reviews with multiple minor issues might receive a more favorable rating than those with a single critical error. Moreover, AMSTAR-2 tends to overemphasize the procedural components of conducting a review, potentially neglecting other crucial elements such as the clinical relevance of the research questions and the accurate interpretation of findings.

The tool also contains ambiguities in some of its critical questions, which may lead to assessment inconsistencies among different reviewers. is the question regarding the analysis of publication bias, which is deemed a critical failure if not conducted, even in scenarios where such analysis may not be applicable due to a limited number of studies (32). This strict adherence to criteria can unjustly penalize reviews that, for methodologically sound reasons, do not perform this analysis. Thus, it is essential for users of AMSTAR-2 to interpret the ratings with caution, acknowledging these limitations and opting for a more comprehensive evaluation of the methodological quality of systematic reviews. Recognizing these constraints is crucial for the effective use of the tool, ensuring that conclusions drawn from its application are both reliable and relevant for clinical practice and health policy development.

Systematic review results indicate that immediate postsurgery cryotherapy effectively reduces pain and swelling, supporting its recognized anti-inflammatory and analgesic effects. The pain reduction achieved through cryotherapy primarily results from the blockade of nerve impulse transmission when local temperatures drop below 14°C, leading to pain perception reduction (17). This effect is influenced by variables such as the size and shape of the ice pack, application duration and frequency, tissue thickness at the application site, and methodological differences across studies (18). Moreover, cooling contributes to reduced postopera-

Carrasco-Labra (2012)570POD3SMD -0.29 (-0.63 to 0.05)InconclusiveCarrasco-Labra (2012)364POD7SMD 0.00 (-0.19 to 0.19)InconclusiveMa (2019)332POD5-7SMD -0.49 (-0.71 to -0.27)Probably beneficialMa (2019)332POD5-7SMD -1.12 (-1.57 to -0.66)BeneficialBailey (2020)474POD1MD -0.94 (-1.38 to -0.59)BeneficialAzab (2022)2218POD5MD -0.97 (-1.26 to -0.69)Probably beneficialAcab (2022)22572POD7MD -0.30 (-0.41 to -0.19)Probably beneficialFalci (2024)200POD1MD -0.97 (-1.26 to -0.69)Probably beneficialFalci (2024)130POD2MD -0.07 (-0.75 to .0.60)No effectFalci (2024)130POD7SMD -0.37 (-0.76 to .0.2)No effectCarrasco-Labra (2012)324POD7SMD -0.37 (-0.76 to .0.2)No effectCarrasco-Labra (2012)324POD7SMD -0.37 (-0.76 to .0.2)No effectMa (2019)518POD2-3SMD -0.37 (-0.76 to .0.2)No effectMa (2019)518POD5-7SMD -0.15 (-0.88 to -0.33)BeneficialMa (2019)518POD5SMD -1.11 (+1.71 to -0.65)BeneficialMa (2019)518POD7SMD -1.11 (+1.71 to -0.65)BeneficialAzab (2022)636POD3SMD -1.11 (+1.71 to -0.65)BeneficialFalci (2024)70POD7SMD -0.01 (-0.51 (-0.66)BeneficialFalci (2024)		Author (year)	Sample Size	Follow-up	Measurement	Effect	
Ma (2019)332POD2-3SMD -0.49 (-0.71 to -0.27)Probably beneficialMa (2019)332POD5-7SMD -1.12 (-1.57 to -0.66)BeneficialBailey (2020)474POD1MD -0.94 (-1.38 to -0.50)BeneficialA Cab (2022)2338POD3MD -0.97 (-1.26 to -0.69)Probably beneficialA Cab (2022)2572POD7MD -0.30 (-0.41 to -0.19)Probably beneficialFalci (2024)200POD1MD -0.50 (-0.83 to -0.17)Probably beneficialFalci (2024)167POD3MD -0.05 (-0.75 to 0.66)No effectFalci (2024)130POD7SMD -0.37 (-0.76 to .02)No effectCarrasco-Labra (2012)342POD3SMD -0.37 (-0.76 to .02)No effectCarrasco-Labra (2012)342POD7SMD -0.37 (-0.76 to .02)No effectMa (2019)518POD5-7SMD -0.51 (-0.68 to -0.33)BeneficialMa (2019)518POD5SMD -0.17 (-1.49 to -0.65)BeneficialAzab (2022)694POD1SMD -1.14 (-1.75 to -0.54)BeneficialAzab (2022)694POD1SMD -1.14 (-1.75 to -0.35)BeneficialAzab (2022)726POD7SMD -0.14 (-0.61 to .016)Probably beneficialFalci (2024)200POD1SMD -0.14 (-0.61 to .016)Probably beneficialFalci (2024)200POD2SMD -0.14 (-0.61 to .016)Probably beneficialFalci (2024)200POD2SMD -0.14 (-0.61 to .016)Probably beneficialFalc		Carrasco-Labra (2012)	570	POD3	SMD -0.29 (-0.63 to 0.05)	Inconclusive	
Ma (2019)         332         POD5-7         SMD -1.12 (-1.57 to -0.66)         Beneficial           Bailey (2020)         474         POD1         MD -0.94 (-1.38 to -0.59)         Beneficial           Azab (2022)         2114         POD1         MD -0.97 (-1.26 to -0.69)         Probably beneficial           Azab (2022)         2572         POD7         MD -0.30 (-0.41 to -0.19)         Probably beneficial           Falci (2024)         200         POD2         MD -0.30 (-0.41 to -0.19)         Probably beneficial           Falci (2024)         167         POD3         MD -0.05 (-0.75 to .0.60)         No effect           Falci (2024)         130         POD7         MD 0.00 (-0.03 to 0.03)         No effect           Carrasco-Labra (2012)         342         POD3         SMD -0.37 (-0.76 to 0.02)         No effect           Ma (2019)         518         POD23         SMD -0.37 (-0.76 to 0.02)         No effect           Ma (2019)         518         POD5-7         SMD -0.37 (-0.75 to -0.09)         Probably beneficial           Ma (2019)         518         POD3         SMD -1.14 (-1.75 to -0.54)         Beneficial           Azab (2022)         694         POD1         SMD -1.04 (-0.51 to -0.54)         Beneficial           Azab (2022)         65		Carrasco-Labra (2012)	364	POD7	SMD 0.00 (-0.19 to 0.19)	Inconclusive	
PainBailey (2020)474POD1MD -0.94 (-1.38 to -0.50)BeneficialAzab (2022)2114POD1MD -1.12 (-1.46 to -0.78)Probably beneficialAzab (2022)2338POD3MD -0.97 (-1.26 to -0.69)Probably beneficialAzab (2022)2372POD1MD -0.30 (-0.41 to -0.19)Probably beneficialFalci (2024)200POD1MD -0.05 (-0.83 to -0.17)Probably beneficialFalci (2024)167POD3MD -0.05 (-0.03 to 0.03)No effectFalci (2024)130POD7MD -0.05 (-0.03 to 0.03)No effectCarrasco-Labra (2012)342POD3SMD -0.37 (-0.76 to 0.02)No effectMa (2019)518POD2-3SMD -0.37 (-0.76 to 0.02)No effectMa (2019)518POD7SMD -0.31 (-0.68 to -0.39)BeneficialBailey (2020)557POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAxab (2022)664POD1SMD -1.14 (-1.77 to -0.54)BeneficialAzab (2022)636POD3SMD -0.14 (-0.61 to -0.16)Probably beneficialFalci (2024)200POD1SMD -0.12 (-1.49 to -0.55)BeneficialFalci (2024)200POD1SMD -0.14 (-0.61 to -0.16)Probably beneficialFalci (2024)706POD3SMD -0.14 (-0.61 to -0.16)Probably beneficialFalci (2024)700POD3SMD -0.14 (-0.61 to -0.37)Probably beneficialFalci (2024)726POD7MD -2.35 (-3.73 to -0.37)Probably benef		Ma (2019)	332	POD2-3	SMD -0.49 (-0.71 to -0.27)	Probably beneficial	
PainAzab (2022)2114POD1MD -1.12 (-1.46 to -0.78)Probably beneficialAzab (2022)2338POD3MD -0.97 (-1.26 to -0.69)Probably beneficialFalci (2024)200POD1MD -0.30 (-0.41 to -0.19)Probably beneficialFalci (2024)200POD2MD -0.50 (-0.81 to -0.81)Probably beneficialFalci (2024)167POD3MD -0.05 (-0.75 to 0.66)No effectFalci (2024)130POD7MD 0.00 (-0.03 to 0.03)No effectCarasco-1.abra (2012)324POD7SMD -0.37 (-0.76 to 0.02)No effectCarasco-1.abra (2012)324POD7SMD -0.51 (-0.39 to 0.10)No effectMa (2019)518POD7SMD -0.51 (-0.68 to -0.33)BeneficialBailey (2020)657POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAzab (2022)664POD1SMD -1.17 (-1.49 to -0.65)BeneficialAzab (2022)6636POD3SMD -1.14 (-1.77 to -0.54)Probably beneficialFalci (2024)200POD7SMD -0.61 (-1.60 to 0.16)Probably beneficialFalci (2024)200POD7SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)200POD7SMD -0.14 (-0.61 to 0.33)InconclusiveCarrasco-Labra (2012)328POD7SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)170POD3SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)170POD3SMD -0.14 (-0.61 to 0.73)Probably b		Ma (2019)	332	POD5-7	SMD -1.12 (-1.57 to -0.66)	Beneficial	
PainAzab (202)2338POD3MD -0.97 (-1.26 to -0.69)Probably beneficialAzab (202)2572POD7MD -0.30 (-0.41 to -0.19)Probably beneficialFalci (2024)200POD1MD -0.30 (-0.41 to -0.19)Probably beneficialFalci (2024)200POD2MD -0.50 (-0.83 to -0.17)Probably beneficialFalci (2024)167POD3MD -0.50 (-0.75 to 0.66)No effectFalci (2024)130POD7MD 0.00 (-0.03 to 0.03)No effectCarrasco-Labra (2012)342POD3SMD -0.37 (-0.76 to 0.02)No effectMa (2019)518POD2-3SMD -0.31 (-0.68 to -0.19)BeneficialMa (2019)518POD2-3SMD -0.51 (-0.68 to -0.19)BeneficialBailey (2020)557POD7MD -0.17 (-1.49 to -0.65)BeneficialAzab (2022)694POD1SMD -1.17 (-1.49 to -0.65)BeneficialAzab (2022)694POD1SMD -1.11 (-1.77 to -0.45)Probably beneficialAzab (2022)676POD3SMD -1.11 (-1.77 to -0.45)Probably beneficialAzab (2022)726POD7SMD -0.06 (-1.16 to -0.16)Probably beneficialFalci (2024)200POD1SMD -0.07 (-0.33 (-0.77)Probably beneficialFalci (2024)80POD7SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)200POD3SMD -0.06 (-1.16 to -0.16)Probably beneficialFalci (2024)130POD7SMD -0.07 (-0.32 to 0.90)No effect <td></td> <td>Bailey (2020)</td> <td>474</td> <td>POD1</td> <td>MD -0.94 (-1.38 to -0.50)</td> <td>Beneficial</td>		Bailey (2020)	474	POD1	MD -0.94 (-1.38 to -0.50)	Beneficial	
Axab (202)2338POD3MD -0.97 (-1.26 to -0.69)Probably beneficialAxab (202)2572POD7MD -0.30 (-0.41 to -0.19)Probably beneficialFalci (2024)200POD1MD -0.36 (-1.55 to -0.81)Probably beneficialFalci (2024)167POD3MD -0.05 (-0.75 to 0.66)No effectFalci (2024)130POD7MD 0.00 (-0.03 to 0.03)No effectCarrasco-Labra(2012)342POD3SMD -0.15 (-0.59 to 0.10)No effectMa (2019)518POD7SMD -0.15 (-0.68 to -0.33)BeneficialMa (2019)518POD7SMD -0.15 (-0.68 to -0.33)BeneficialMa (2019)518POD5SMD -1.14 (-1.75 to -0.64)BeneficialAxab (2022)694POD1SMD -1.14 (-1.75 to -0.54)BeneficialAxab (2022)726POD7SMD -0.17 (-1.49 to -0.55)BeneficialAzab (2022)726POD7SMD -0.14 (-0.61 to -3.30)InconclusiveFalci (2024)200POD1SMD -0.14 (-1.75 to -0.54)BeneficialFalci (2024)200POD1SMD -0.14 (-0.61 to -3.30)InconclusiveFalci (2024)70POD3SMD -0.14 (-0.61 to -3.30)InconclusiveFalci (2024)70POD3SMD -0.14 (-0.61 to -3.30)InconclusiveFalci (2024)700POD1SMD -0.14 (-0.61 to -3.30)InconclusiveFalci (2024)700POD3SMD -0.14 (-0.61 to -3.30)InconclusiveFalci (2024)70POD3SMD		Azab (2022)	2114	POD1	MD -1.12 (-1.46 to -0.78)	Probably beneficial	
Falci (2024)200POD1MD -1.08 (-1.35 to -0.81)Probably beneficialFalci (2024)200POD2MD -0.50 (-0.83 to -0.17)Probably beneficialFalci (2024)167POD3MD -0.05 (-0.75 to 0.66)No effectFalci (2024)130POD7MD 0.00 (-0.03 to 0.03)No effectCarrasco-Labra (2012)342POD7SMD -0.37 (-0.76 to 0.02)No effectCarrasco-Labra (2012)324POD7SMD -0.35 (-0.76 to 0.02)No effectMa (2019)518POD5-7SMD -0.31 (-0.68 to -0.33)BeneficialMa (2019)518POD5-7SMD -1.07 (1.49 to -0.65)BeneficialAzab (2022)694POD1SMD -1.07 (1.49 to -0.65)BeneficialAzab (2022)694POD1SMD -1.11 (-1.77 to -0.45)Probably beneficialAzab (2022)726POD7SMD -1.14 (-1.75 to -0.54)BeneficialFalci (2024)200POD1SMD -1.14 (-1.75 to -0.64)Probably beneficialFalci (2024)200POD2SMD -0.14 (-0.61 to -0.16)Probably beneficialFalci (2024)200POD2SMD -0.14 (-0.61 to -0.33)InconclusiveFalci (2024)200POD3SMD -0.14 (-0.61 to -0.34)InconclusiveFalci (2024)100POD3SMD -0.14 (-0.61 to -0.35)Probably beneficialFalci (2024)130POD7MD -0.23 (-4.33 to -0.37)Probably beneficialFalci (2024)130POD7MD -2.35 (-4.33 to -0.37)Probably beneficial <tr<< td=""><td>Pain</td><td>Azab (2022)</td><td>2338</td><td>POD3</td><td>MD -0.97 (-1.26 to -0.69)</td><td>Probably beneficial</td></tr<<>	Pain	Azab (2022)	2338	POD3	MD -0.97 (-1.26 to -0.69)	Probably beneficial	
Falci (2024)200POD2MD -0.50 (-0.83 to -0.17)Probably beneficialFalci (2024)167POD3MD -0.05 (-0.75 to 0.66)No effectFalci (2024)130POD7MD 0.00 (-0.03 to 0.03)No effectCarrasco-Labra (2012)342POD3SMD -0.37 (-0.76 to 0.02)No effectCarrasco-Labra (2012)324POD3SMD -0.15 (-0.39 to 0.10)No effectMa (2019)518POD2-3SMD -0.35 (-0.54 to -0.19)BeneficialMa (2019)518POD5-7SMD -0.31 (-0.54 to -0.19)BeneficialBailey (2020)557POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAzab (2022)664POD1SMD -1.17 (-1.49 to -0.65)BeneficialAzab (2022)636POD3SMD -1.14 (-1.75 to -0.54)BeneficialFalci (2024)200POD1SMD -1.12 (-2.34 to -0.11)Probably beneficialFalci (2024)200POD2SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)70POD3SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)200POD7SMD -0.37 (-0.37)Probably beneficialFalci (2024)152POD7MD -2.35 (-4.31 to -0.37)BeneficialFalci (2024)152POD7MD -2.35 (-4.31 to -0.37)Probably beneficialFalci (2024)154POD7MD -2.58 (-3.75 to -1.42)BeneficialBailey (2020)274POD7MD -2.58 (-3.75 to -2.79)BeneficialFalci (2024)130 <td< td=""><td></td><td>Azab (2022)</td><td>2572</td><td>POD7</td><td>MD -0.30 (-0.41 to -0.19)</td><td colspan="2">Probably beneficial</td></td<>		Azab (2022)	2572	POD7	MD -0.30 (-0.41 to -0.19)	Probably beneficial	
Falci (2024)167POD3MD -0.05 (-0.75 to 0.66)No effectFalci (2024)130POD7MD 0.00 (-0.03 to 0.03)No effectCarrasco-Labra (2012)342POD3SMD -0.37 (-0.76 to 0.02)No effectMa (2019)518POD2-3SMD -0.36 (-0.54 to -0.19)BeneficialMa (2019)518POD5-7SMD -0.36 (-0.54 to -0.19)BeneficialBailey (2020)657POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAzab (2022)664POD1SMD -1.14 (-1.75 to -0.54)BeneficialAzab (2022)636POD3SMD -1.14 (-1.75 to -0.54)BeneficialAzab (2022)726POD7SMD -1.14 (-1.75 to -0.54)BeneficialFalci (2024)200POD1SMD -1.23 (-2.34 to -0.11)Probably beneficialFalci (2024)200POD2SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)200POD7MD -3.72 (-6.03 to -1.42)BeneficialFalci (2024)200POD7MD 0.29 (-0.32 to 0.90)No effectFalci (2024)1552POD7MD 0.29 (-0.32 to 0.90)No effectBailey (2020)274POD3MD -4.14 (-5.84 to -2.45)BeneficialFalci (2024)130POD3SMD -1.04 (-1.41 -0.67)Probably beneficialFalci (2024)130POD3SMD -1.04 (-1.41 -0.67)Probably beneficialFalci (2024)130POD3SMD -1.26 (-3.14 to .25)BeneficialFalci (2024)130POD3SMD -1		Falci (2024)	200	POD1	MD -1.08 (-1.35 to -0.81)	Probably beneficial	
Falci (2024)130POD7MD 0.00 (-0.03 to 0.03)No effectCarrasco-Labra (2012)342POD3SMD -0.37 (-0.76 to 0.02)No effectCarrasco-Labra (2012)324POD7SMD -0.15 (-0.39 to 0.10)No effectMa (2019)518POD2-3SMD -0.36 (-0.54 to -0.19)BeneficialMa (2019)518POD5SMD -0.51 (-0.68 to -0.33)BeneficialBailey (2020)657POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAzab (2022)694POD1SMD -1.07 (-1.49 to -0.65)BeneficialAzab (2022)636POD3SMD -1.11 (-1.77 to -0.45)Probably beneficialFalci (2024)200POD1SMD -1.23 (-2.34 to -0.11)Probably beneficialFalci (2024)200POD2SMD -0.66 (-1.16 to -0.16)Probably beneficialFalci (2024)700POD7SMD -0.07 (-1.49 to 0.65)BeneficialCarrasco-Labra (2012)428POD3SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)700POD7SMD -0.06 (-1.16 to -0.16)Probably beneficialCarrasco-Labra (2012)428POD7MD -2.35 (-4.33 to -0.37)Probably beneficialCarrasco-Labra (2012)428POD7MD -2.35 (-4.33 to -0.37)Probably beneficialCarrasco-Labra (2012)1552POD1MD -2.35 (-4.33 to -0.37)Probably beneficialCarrasco-Labra (2012)1552POD1MD -2.58 (-3.75 to -1.47)BeneficialAzab (2022)1552POD1MD -2.58 (-3		Falci (2024)	200	POD2	MD -0.50 (-0.83 to -0.17)		
Carrasco-Labra (2012)342POD3SMD -0.37 (-0.76 to 0.02)No effectCarrasco-Labra (2012)324POD7SMD -0.15 (-0.39 to 0.10)No effectMa (2019)518POD2-3SMD -0.36 (-0.54 to -0.19)BeneficialBailey (2020)557POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAzab (2022)694POD1SMD -1.07 (-1.49 to -0.65)BeneficialAzab (2022)694POD3SMD -1.14 (-1.75 to -0.45)Probably beneficialAzab (2022)694POD1SMD -1.11 (-1.77 to -0.45)Probably beneficialFalci (2024)200POD2SMD -0.12 (-2.34 to -0.11)Probably beneficialFalci (2024)200POD2SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)70POD3SMD -0.14 (-0.61 to 0.33)InconclusiveCarrasco-Labra (2012)428POD7MD 0.29 (-0.32 to 0.90)No effectCarrasco-Labra (2012)328POD7MD 0.29 (-0.32 to 0.90)No effectMaiey (2020)274POD7MD 0.29 (-0.32 to 0.90)No effectAzab (2022)1552POD1MD -4.25 (-5.70 to -2.79)BeneficialAzab (2022)1540POD3MD -1.44 (-5.84 to -2.45)BeneficialAzab (2022)1540POD3MD -4.25 (-3.75 to -1.41)Probably beneficialAzab (2022)1552POD1MD -2.35 (-3.75 to -1.41)Probably beneficialAzab (2022)1552POD1MD -2.35 (-3.75 to -1.41)Probably beneficial<		Falci (2024)	167	POD3	MD -0.05 (-0.75 to 0.66)	No effect	
Carrasco-Labra (2012)324POD7SMD -0.15 (-0.39 to 0.10)No effectMa (2019)518POD2-3SMD -0.36 (-0.54 to -0.19)BeneficialMa (2019)518POD5-7SMD -0.51 (-0.68 to -0.33)BeneficialBailey (2020)557POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAzab (2022)694POD1SMD -1.07 (-1.49 to -0.65)BeneficialAzab (2022)636POD3SMD -1.14 (-1.75 to -0.54)BeneficialAzab (2022)726POD7SMD -1.23 (-2.34 to -0.11)Probably beneficialFalci (2024)200POD1SMD -0.66 (-1.16 to -0.16)Probably beneficialFalci (2024)200POD2SMD -0.66 (-1.16 to -0.16)Probably beneficialFalci (2024)70POD3SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)80POD7SMD 0.00 (-0.44 to 0.44)InconclusiveCarrasco-Labra (2012)428POD3MD -3.72 (-6.03 to -1.42)BeneficialCarrasco-Labra (2012)328POD7MD -2.35 (-4.33 to -0.37)Probably beneficialCarrasco-Labra (2012)1552POD1MD -4.25 (-5.70 to -2.79)BeneficialTrismusAzab (2022)1540POD3MD -4.14 (-5.84 to -2.45)BeneficialAzab (2022)1540POD7MD -2.58 (-3.75 to -1.41)Probably beneficialFalci (2024)130POD7SMD -1.04 (-1.41 to -0.67)Probably beneficialFalci (2024)130POD7SMD -1.26 (-3.14 to 0.62) <td></td> <td>Falci (2024)</td> <td>130</td> <td>POD7</td> <td>MD 0.00 (-0.03 to 0.03)</td> <td>No effect</td>		Falci (2024)	130	POD7	MD 0.00 (-0.03 to 0.03)	No effect	
Heat Betwein Instruct Instruc		Carrasco-Labra (2012)	342	POD3	SMD -0.37 (-0.76 to 0.02)	No effect	
Ha         Ma         Simple         POD5-7         SMD -0.51 (-0.68 to -0.33)         Beneficial           Bailey         (2020)         557         POD7         MD -0.33 (-0.57 to -0.09)         Probably beneficial           Azab         (2022)         694         POD1         SMD -1.07 (-1.49 to -0.65)         Beneficial           Azab         (2022)         636         POD3         SMD -1.14 (-1.75 to -0.54)         Beneficial           Azab         (2022)         726         POD7         SMD -1.23 (-2.34 to -0.11)         Probably beneficial           Falci         (2024)         200         POD2         SMD -0.66 (-1.16 to -0.16)         Probably beneficial           Falci         (2024)         70         POD3         SMD -0.01 (-0.61 to 0.33)         Inconclusive           Falci         (2024)         80         POD7         SMD 0.00 (-0.44 to 0.44)         Inconclusive           Carrasco-Labra (2012)         428         POD3         MD -3.72 (-6.03 to -1.42)         Beneficial           Carrasco-Labra (2012)         1328         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Azab (2022)         1552         POD1         MD -4.14 (-5.84 to -2.45)         Beneficial           Azab (2022)         1782         <		Carrasco-Labra (2012)	324	POD7	SMD -0.15 (-0.39 to 0.10)	No effect	
Bailey (2020)557POD7MD -0.33 (-0.57 to -0.09)Probably beneficialAzab (2022)694POD1SMD -1.07 (-1.49 to -0.65)BeneficialAzab (2022)636POD3SMD -1.14 (-1.75 to -0.54)BeneficialAzab (2022)726POD7SMD -1.14 (-1.75 to -0.54)Probably beneficialFalci (2024)200POD1SMD -1.23 (-2.34 to -0.11)Probably beneficialFalci (2024)200POD2SMD -0.66 (-1.16 to -0.16)Probably beneficialFalci (2024)70POD3SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)80POD7SMD 0.00 (-0.44 to 0.44)InconclusiveCarrasco-Labra (2012)428POD3MD -3.72 (-6.03 to -1.42)BeneficialCarrasco-Labra (2012)328POD7MD 0.29 (-0.32 to 0.90)No effectBailey (2020)274POD7MD 0.29 (-0.32 to 0.90)No effectAzab (2022)1552POD1MD -4.25 (-5.70 to -2.79)BeneficialAzab (2022)1552POD7MD -2.58 (-3.75 to -1.41)Probably beneficialAzab (2022)1782POD7SMD -1.04 (-1.41 to -0.67)Probably beneficialFalci (2024)130POD7SMD -1.26 (-3.14 to 0.62)No effectBleedingFalci (2024)130POD7SMD -1.26 (-3.14 to 0.62)No effectMoundfalci (2024)130POD7SMD -1.26 (-3.14 to 0.62)No effectBleedingAzab (2022)6962-31 daysRD 0.00 (-0.04 to 0.04) <td></td> <td>Ma (2019)</td> <td>518</td> <td>POD2-3</td> <td>SMD -0.36 (-0.54 to -0.19)</td> <td>Beneficial</td>		Ma (2019)	518	POD2-3	SMD -0.36 (-0.54 to -0.19)	Beneficial	
Edema         Azab (2022)         694         POD1         SMD -1.07 (-1.49 to -0.65)         Beneficial           Azab (2022)         636         POD3         SMD -1.14 (-1.75 to -0.54)         Beneficial           Azab (2022)         726         POD7         SMD -1.11 (-1.77 to -0.45)         Probably beneficial           Falci (2024)         200         POD1         SMD -1.23 (-2.34 to -0.11)         Probably beneficial           Falci (2024)         200         POD2         SMD -0.16 (-1.16 to -0.16)         Probably beneficial           Falci (2024)         70         POD3         SMD -0.14 (-0.61 to 0.33)         Inconclusive           Falci (2024)         80         POD7         SMD 0.00 (-0.44 to 0.44)         Inconclusive           Carrasco-Labra (2012)         428         POD3         MD -3.72 (-6.03 to -1.42)         Beneficial           Carrasco-Labra (2012)         328         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Bailey (2020)         274         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Azab (2022)         1552         POD1         MD -4.25 (-5.70 to -2.79)         Beneficial           Azab (2022)         1540         POD3         MD -1.41 (-5.84 to -2.45)         Beneficial           F		Ma (2019)	518	POD5-7	SMD -0.51 (-0.68 to -0.33)	Beneficial	
Edema         Azab (2022)         636         POD3         SMD -1.14 (-1.75 to -0.54)         Beneficial           Azab (2022)         726         POD7         SMD -1.11 (-1.77 to -0.45)         Probably beneficial           Falci (2024)         200         POD1         SMD -1.23 (-2.34 to -0.11)         Probably beneficial           Falci (2024)         200         POD2         SMD -0.66 (-1.16 to -0.16)         Probably beneficial           Falci (2024)         70         POD3         SMD -0.14 (-0.61 to 0.33)         Inconclusive           Falci (2024)         80         POD7         SMD 0.00 (-0.44 to 0.44)         Inconclusive           Garrasco-Labra (2012)         428         POD3         MD -3.72 (-6.03 to -1.42)         Beneficial           Carrasco-Labra (2012)         328         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Azab (2022)         1552         POD1         MD -4.25 (-5.70 to -2.79)         Beneficial           Mazab (2022)         1552         POD1         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Azab (2022)         1782         POD7         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Falci (2024)         130         POD1         SMD -1.04 (-1.41 to -0.67)         Probably beneficial		Bailey (2020)	557	POD7	MD -0.33 (-0.57 to -0.09)	Probably beneficial	
Azab (2022)         636         POD3         SMD -1.14 (-1.75 to -0.54)         Beneficial           Azab (2022)         726         POD7         SMD -1.11 (-1.77 to -0.45)         Probably beneficial           Falci (2024)         200         POD1         SMD -1.23 (-2.34 to -0.11)         Probably beneficial           Falci (2024)         200         POD2         SMD -0.66 (-1.16 to -0.16)         Probably beneficial           Falci (2024)         70         POD3         SMD -0.14 (-0.61 to 0.33)         Inconclusive           Falci (2024)         80         POD7         SMD 0.00 (-0.44 to 0.44)         Inconclusive           Carrasco-Labra (2012)         428         POD3         MD -3.72 (-6.03 to -1.42)         Beneficial           Carrasco-Labra (2012)         328         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Azab (2022)         1552         POD1         MD -4.25 (-5.70 to -2.79)         Beneficial           Azab (2022)         1552         POD1         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Azab (2022)         1782         POD7         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Falci (2024)         130         POD2         SMD -1.26 (-3.14 to 0.62)         No effect           Fala	<b>F</b> 1	Azab (2022)	694	POD1	SMD -1.07 (-1.49 to -0.65)	Beneficial	
Falci (2024)         200         POD1         SMD -1.23 (-2.34 to -0.1))         Probably beneficial           Falci (2024)         200         POD2         SMD -0.66 (-1.16 to -0.16)         Probably beneficial           Falci (2024)         70         POD3         SMD -0.14 (-0.61 to 0.33)         Inconclusive           Falci (2024)         80         POD7         SMD 0.00 (-0.44 to 0.44)         Inconclusive           Carrasco-Labra (2012)         428         POD3         MD -3.72 (-6.03 to -1.42)         Beneficial           Carrasco-Labra (2012)         328         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Bailey (2020)         274         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Azab (2022)         1552         POD1         MD -4.25 (-5.70 to -2.79)         Beneficial           Azab (2022)         1540         POD3         MD -4.14 (-5.84 to -2.45)         Beneficial           Azab (2022)         1782         POD7         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Falci (2024)         130         POD7         SMD -1.04 (-1.41 to -0.67)         Probably beneficial           Falci (2024)         130         POD7         SMD -1.26 (-3.14 to 0.62)         No effect           Falci (2024) </td <td>Edema</td> <td>Azab (2022)</td> <td>636</td> <td>POD3</td> <td>SMD -1.14 (-1.75 to -0.54)</td> <td>Beneficial</td>	Edema	Azab (2022)	636	POD3	SMD -1.14 (-1.75 to -0.54)	Beneficial	
Falci (2024)200POD2SMD -0.66 (-1.16 to -0.16)Probably beneficialFalci (2024)70POD3SMD -0.14 (-0.61 to 0.33)InconclusiveFalci (2024)80POD7SMD 0.00 (-0.44 to 0.44)InconclusiveCarrasco-Labra (2012)428POD3MD -3.72 (-6.03 to -1.42)BeneficialCarrasco-Labra (2012)328POD7MD 0.29 (-0.32 to 0.90)No effectBailey (2020)274POD7MD 0.29 (-0.32 to 0.90)No effectAzab (2022)1552POD1MD -4.25 (-5.70 to -2.79)BeneficialAzab (2022)1540POD3MD -4.14 (-5.84 to -2.45)BeneficialAzab (2022)1782POD7MD 2.58 (-3.75 to -1.41)Probably beneficialFalci (2024)130POD1SMD -1.04 (-1.41 to -0.67)Probably beneficialFalci (2024)130POD7SMD -1.26 (-3.14 to 0.62)No effectBleedingBailey (2020)8230 daysRR 2.45 (0.68 to 8.82)InconclusiveMountAzab (2022)10022.31 daysRD 0.00 (-0.04 to 0.04)No effectMountBailey (2020)821 weekRR 0.51 (0.18 to 1.47)No effectAzab (2022)10022.31 daysRD 0.01 (-0.02 to 0.03)No effectAzab (2022)10022.31 daysRD 0.01 (-0.02 to 0.03)No effectAzab (2022)10022.31 daysRD 0.01 (-0.02 to 0.03)No effectBailey (2020)821 weekRR 0.51 (0.18 to 1.47)No effect <t< td=""><td></td><td>Azab (2022)</td><td>726</td><td>POD7</td><td>SMD -1.11 (-1.77 to -0.45)</td><td>Probably beneficial</td></t<>		Azab (2022)	726	POD7	SMD -1.11 (-1.77 to -0.45)	Probably beneficial	
Falci (2024)         70         POD3         SMD -0.14 (-0.61 to 0.33)         Inconclusive           Falci (2024)         80         POD7         SMD 0.00 (-0.44 to 0.44)         Inconclusive           Carrasco-Labra (2012)         428         POD3         MD -3.72 (-6.03 to -1.42)         Beneficial           Carrasco-Labra (2012)         328         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Bailey (2020)         274         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Azab (2022)         1552         POD1         MD -4.25 (-5.70 to -2.79)         Beneficial           Azab (2022)         1552         POD7         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Azab (2022)         1782         POD7         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Falci (2024)         130         POD1         SMD -1.04 (-1.41 to -0.67)         Probably beneficial           Falci (2024)         130         POD7         SMD -1.26 (-3.14 to 0.62)         No effect           Baleeding         Azab (2022)         696         2-31 days         RR 0.51 (0.18 to 1.47)         No effect           Mount         infection         Bailey (2020)         82         1 week         RR 0.51 (0.18 to 1.47)		Falci (2024)	200	POD1	SMD -1.23 (-2.34 to -0.11)	Probably beneficial	
Falci (2024)         80         POD7         SMD 0.00 (-0.44 to 0.44)         Inconclusive           Carrasco-Labra (2012)         428         POD3         MD -3.72 (-6.03 to -1.42)         Beneficial           Carrasco-Labra (2012)         328         POD7         MD -2.35 (-4.33 to -0.37)         Probably beneficial           Bailey (2020)         274         POD7         MD 0.29 (-0.32 to 0.90)         No effect           Azab (2022)         1552         POD1         MD -4.25 (-5.70 to -2.79)         Beneficial           Azab (2022)         1540         POD3         MD -4.14 (-5.84 to -2.45)         Beneficial           Azab (2022)         1782         POD7         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Falci (2024)         130         POD1         SMD -1.04 (-1.41 to -0.67)         Probably beneficial           Falci (2024)         130         POD7         SMD -1.26 (-3.14 to 0.62)         No effect           Falci (2024)         130         POD7         SMD -1.04 (-1.41 to -0.67)         No effect           Bleeding         Azab (2022)         696         2-31 days         RR 2.45 (0.68 to 8.82)         Inconclusive           Mount         Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect		Falci (2024)	200	POD2	SMD -0.66 (-1.16 to -0.16)	Probably beneficial	
Carrasco-Labra (2012)428POD3MD -3.72 (-6.03 to -1.42)BeneficialCarrasco-Labra (2012)328POD7MD -2.35 (-4.33 to -0.37)Probably beneficialBailey (2020)274POD7MD 0.29 (-0.32 to 0.90)No effectAzab (2022)1552POD1MD -4.25 (-5.70 to -2.79)BeneficialAzab (2022)1540POD3MD -4.14 (-5.84 to -2.45)BeneficialAzab (2022)1782POD7MD -2.58 (-3.75 to -1.41)Probably beneficialFalci (2024)130POD1SMD -1.04 (-1.41 to -0.67)Probably beneficialFalci (2024)130POD7SMD -1.26 (-3.14 to 0.62)No effectBleedingBailey (2020)8230 daysRR 2.45 (0.68 to 8.82)InconclusiveWound infectionCarrasco-Labra (2012)6201 weekRR 0.51 (0.18 to 1.47)No effectBailey (2020)821 weekRR 0.51 (0.18 to 1.47)No effectAzab (2022)10022-31 daysRD 0.01 (-0.02 to 0.03)No effectAlveolitisBailey (2020)3751 weekRR 0.51 (0.18 to 1.47)No effect		Falci (2024)	70	POD3	SMD -0.14 (-0.61 to 0.33)	Inconclusive	
Carrasco-Labra (2012)328POD7MD -2.35 (-4.33 to -0.37)Probably beneficialBailey (2020)274POD7MD 0.29 (-0.32 to 0.90)No effectAzab (2022)1552POD1MD -4.25 (-5.70 to -2.79)BeneficialAzab (2022)1540POD3MD -4.14 (-5.84 to -2.45)BeneficialAzab (2022)1782POD7MD -2.58 (-3.75 to -1.41)Probably beneficialFalci (2024)130POD1SMD -1.04 (-1.41 to -0.67)Probably beneficialFalci (2024)130POD7SMD -1.26 (-3.14 to 0.62)No effectBleedingBailey (2020)8230 daysRR 2.45 (0.68 to 8.82)InconclusiveWound infectionCarrasco-Labra (2012)6201 weekRR 0.51 (0.18 to 1.47)No effectAzab (2022)10022-31 daysRD 0.01 (-0.02 to 0.03)No effectAlveolitisBailey (2020)3751 weekRR 1.01 (0.42 to 2.44)No effect		Falci (2024)	80	POD7	SMD 0.00 (-0.44 to 0.44)	Inconclusive	
Bailey (2020) $274$ POD7MD 0.29 (-0.32 to 0.90)No effectAzab (2022)1552POD1MD -4.25 (-5.70 to -2.79)BeneficialAzab (2022)1540POD3MD -4.14 (-5.84 to -2.45)BeneficialAzab (2022)1782POD7MD -2.58 (-3.75 to -1.41)Probably beneficialFalci (2024)130POD1SMD -1.04 (-1.41 to -0.67)Probably beneficialFalci (2024)130POD2SMD -1.54 (-3.31 to 0.23)No effectBleedingBailey (2020)8230 daysRR 2.45 (0.68 to 8.82)InconclusiveWound infectionCarrasco-Labra (2012)6201 weekRR 0.51 (0.18 to 1.47)No effectAzab (2022)10022-31 daysRD 0.01 (-0.02 to 0.03)No effectAlveolitisBailey (2020)3751 weekRR 0.51 (0.18 to 1.47)No effectAlveolitisBailey (2020)3751 weekRR 0.51 (0.18 to 1.47)No effect		Carrasco-Labra (2012)	428	POD3	MD -3.72 (-6.03 to -1.42)	Beneficial	
Azab (2022)         1552         POD1         MD -4.25 (-5.70 to -2.79)         Beneficial           Azab (2022)         1540         POD3         MD -4.14 (-5.84 to -2.45)         Beneficial           Azab (2022)         1782         POD7         MD -2.58 (-3.75 to -1.41)         Probably beneficial           Falci (2024)         130         POD1         SMD -1.04 (-1.41 to -0.67)         Probably beneficial           Falci (2024)         130         POD2         SMD -1.54 (-3.31 to 0.23)         No effect           Falci (2024)         130         POD7         SMD -1.26 (-3.14 to 0.62)         No effect           Bleeding         Bailey (2020)         82         30 days         RR 2.45 (0.68 to 8.82)         Inconclusive           Wound infection         Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect           Bailey (2020)         82         1 week         RR 0.51 (0.18 to 1.47)         No effect           Mound infection         Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         <		Carrasco-Labra (2012)	328	POD7	MD -2.35 (-4.33 to -0.37)	Probably beneficial	
TrismusAzab (2022)1540POD3MD -4.14 (-5.84 to -2.45)BeneficialAzab (2022)1782POD7MD -2.58 (-3.75 to -1.41)Probably beneficialFalci (2024)130POD1SMD -1.04 (-1.41 to -0.67)Probably beneficialFalci (2024)130POD2SMD -1.54 (-3.31 to 0.23)No effectFalci (2024)130POD7SMD -1.26 (-3.14 to 0.62)No effectBleedingBailey (2020)8230 daysRR 2.45 (0.68 to 8.82)InconclusiveMoundAzab (2022)6962-31 daysRD 0.00 (-0.04 to 0.04)No effectBailey (2020)821 weekRR 0.51 (0.18 to 1.47)No effectMoundBailey (2020)821 weekRR 0.21 (0.01 to 4.24)InconclusiveAzab (2022)10022-31 daysRD 0.01 (-0.02 to 0.03)No effectAlveolitisBailey (2020)3751 weekRR 0.51 (0.18 to 1.47)No effectAlveolitisBailey (2020)3751 weekRR 0.51 (0.18 to 1.47)No effect		Bailey (2020)	274	POD7	MD 0.29 (-0.32 to 0.90)	No effect	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Azab (2022)	1552	POD1	MD -4.25 (-5.70 to -2.79)	Beneficial	
Falci (2024)         130         POD1         SMD -1.04 (-1.41 to -0.67)         Probably beneficial           Falci (2024)         130         POD2         SMD -1.54 (-3.31 to 0.23)         No effect           Falci (2024)         130         POD7         SMD -1.26 (-3.14 to 0.62)         No effect           Bleeding         Bailey (2020)         82         30 days         RR 2.45 (0.68 to 8.82)         Inconclusive           Mound infection         Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect           Mound infection         Bailey (2020)         82         1 week         RR 0.51 (0.18 to 1.47)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect	Trismus	Azab (2022)	1540	POD3	MD -4.14 (-5.84 to -2.45)	Beneficial	
Falci (2024)         130         POD2         SMD -1.54 (-3.31 to 0.23)         No effect           Falci (2024)         130         POD7         SMD -1.26 (-3.14 to 0.62)         No effect           Bleeding         Bailey (2020)         82         30 days         RR 2.45 (0.68 to 8.82)         Inconclusive           Mound infection         Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect           Mound infection         Bailey (2020)         82         1 week         RR 0.51 (0.18 to 1.47)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Azab (2022)	1782	POD7	MD -2.58 (-3.75 to -1.41)	Probably beneficial	
Falci (2024)         130         POD7         SMD -1.26 (-3.14 to 0.62)         No effect           Bleeding         Bailey (2020)         82         30 days         RR 2.45 (0.68 to 8.82)         Inconclusive           Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect           Wound infection         Carrasco-Labra (2012)         620         1 week         RR 0.51 (0.18 to 1.47)         No effect           Bailey (2020)         82         1 week         RR 0.21 (0.01 to 4.24)         Inconclusive           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Falci (2024)	130	POD1	SMD -1.04 (-1.41 to -0.67)	Probably beneficial	
Bleeding         Bailey (2020)         82         30 days         RR 2.45 (0.68 to 8.82)         Inconclusive           Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect           Wound infection         Carrasco-Labra (2012)         620         1 week         RR 0.51 (0.18 to 1.47)         No effect           Bailey (2020)         82         1 week         RR 0.21 (0.01 to 4.24)         Inconclusive           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Falci (2024)	130	POD2	SMD -1.54 (-3.31 to 0.23)	No effect	
Bleeding         Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect           Wound infection         Carrasco-Labra (2012)         620         1 week         RR 0.51 (0.18 to 1.47)         No effect           Bailey (2020)         82         1 week         RR 0.21 (0.01 to 4.24)         Inconclusive           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Falci (2024)	130	POD7	SMD -1.26 (-3.14 to 0.62)	No effect	
Mound infection         Azab (2022)         696         2-31 days         RD 0.00 (-0.04 to 0.04)         No effect           Wound infection         Carrasco-Labra (2012)         620         1 week         RR 0.51 (0.18 to 1.47)         No effect           Bailey (2020)         82         1 week         RR 0.21 (0.01 to 4.24)         Inconclusive           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Bailey (2020)	82	30 days	RR 2.45 (0.68 to 8.82)	Inconclusive	
Wound infection         Bailey (2020)         82         1 week         RR 0.21 (0.01 to 4.24)         Inconclusive           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Carrasco-Labra (2012)         620         1 week         RR 0.51 (0.18 to 1.47)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Azab (2022)	696	2-31 days	RD 0.00 (-0.04 to 0.04)	No effect	
infection         Bailey (2020)         82         1 week         RR 0.21 (0.01 to 4.24)         Inconclusive           Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Carrasco-Labra (2012)         620         1 week         RR 0.51 (0.18 to 1.47)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Carrasco-Labra (2012)	620	1 week	RR 0.51 (0.18 to 1.47)	No effect	
Azab (2022)         1002         2-31 days         RD 0.01 (-0.02 to 0.03)         No effect           Carrasco-Labra (2012)         620         1 week         RR 0.51 (0.18 to 1.47)         No effect           Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect		Bailey (2020)	82	1 week	RR 0.21 (0.01 to 4.24)	Inconclusive	
Alveolitis         Bailey (2020)         375         1 week         RR 1.01 (0.42 to 2.44)         No effect	meetion	Azab (2022)	1002	2-31 days	RD 0.01 (-0.02 to 0.03)	No effect	
		Carrasco-Labra (2012)	620	1 week	RR 0.51 (0.18 to 1.47)	No effect	
Azab (2022)         1598         20-31 days         RD 0.01 (-0.02 to 0.04)         No effect	Alveolitis	Bailey (2020)	375	1 week	RR 1.01 (0.42 to 2.44)	No effect	
		Azab (2022)	1598	20-31 days	RD 0.01 (-0.02 to 0.04)	No effect	

**Table 3:** Synthesis of extracted data on secondary versus primary closure for reduction of pain, edema, and trismus, and prevention of bleeding, surgical wound infection, and alveolitis after third molar removal.

POD1, first postoperative day; POD2, second postoperative day; POD3, third postoperative day; POD7, seventh postoperative day; POD2-3, between the second and third postoperative days; POD5-7, between the fifth and seventh postoperative days; MD, mean difference; SMD, standardized mean difference; RR, relative risk; RD, risk difference.

Negative effect measures for continuous outcomes indicated favorability towards secondary closure.

	Author (year)	Formulations	Sample Size	Measurement	Effect
	Caso (2005)	Rinse vs. Control	825	RR 0.53 (0.41 to 0.69)	Probably beneficial
	Rodríguez-Sánchez (2017)	Rinse vs. Control	1096	RR 0.58 (0.47 to 0.71)	Probably beneficial
	Rodríguez-Sánchez (2017)	Gel vs. Control	1074	RR 0.47 (0.37 to 0.60)	Probably beneficial
	Teshome (2017)	Gel vs. Control	968	RR 0.43 (0.32 to 0.58)	Probably beneficial
Alveolite	Zhou (2017)	Gel vs. Control	1043	OR 0.40 (0.28 to 0.55)	Probably beneficial
	Daly (2022)	Rinse vs. Control	1600	OR 0.38 (0.25 to 0.58)	Beneficial
	Daly (2022)	Gel vs. Control	833	OR 0.44 (0.27 to 0.71)	Probably beneficial
	Romero-Olid (2023)	Gel vs. Control	1523	RR 0.40 (0.31 to 0.51)	Probably beneficial
	Romero-Olid (2023)	Rinse vs. Control	2679	RR 0.50 (0.41 to 0.62)	Probably beneficial

Table 4: Synthesis of extracted data on chlorhexidine for prevention of alveolitis after third molar extraction.

RR, relative risk; OR, odds ratio.

tive swelling through its vasoconstrictive effects, which decrease neutrophil activity and inflammatory cytokine release, thus mitigating fluid accumulation (17). However, the results of reducing trismus are inconsistent, suggesting a need for more standardized cryotherapy protocols and further research into its optimal application parameters.

Traditional suturing techniques following third molar extractions aim to promote primary wound closure and minimize risks of postoperative bleeding and infection (33). However, emerging evidence suggests that secondary wound closure, which involves leaving the wound partially open, may more effectively alleviate pain and swelling post-surgery. This method promotes the interaction between the alveolus and the oral cavity, facilitating better drainage of inflammation (34). In contrast, suturing can induce trauma, damage capillaries, and trigger pro-inflammatory cytokines release, increasing vascular permeability and consequently swelling (35). Despite these potential benefits, the data regarding secondary closure's effectiveness in reducing trismus, bleeding, and infection risks remain inconsistent and limited, underscoring the need for additional research to establish the efficacy of secondary closure across various clinical outcomes.

In recent years, chlorhexidine has become increasingly popular as an antiseptic in medicine and dentistry, favored for its antimicrobial efficacy, low cost, and ease of application (36). Particularly when used as a mouthwash, the best evidence indicates that chlorhexidine is effective in reducing postoperative alveolitis, while its application in gel form is considered probably beneficial in preventing this complication. The effectiveness of chlorhexidine is derived from its ability to disrupt biofilms and diminish oral pathogen loads (37), attributable to its broad-spectrum antimicrobial activity against both gram-positive and gram-negative bacteria. It functions as a bacteriostatic agent at lower doses and exhibits bactericidal properties at higher concentrations, with additional antifungal effects (38).

It is noteworthy that none of the systematic reviews included in this study assessed the impact of interventions on patients' quality of life, a key outcome for patientcentered evaluations. The omission of this critical dimension is concerning, as comprehending patients' quality of life, satisfaction, and overall well-being is essential for informed decision-making and tailoring treatments to optimize patient experiences during third molar surgeries (1). This research gap significantly hinders our understanding and limits our ability to provide personalized care that aligns with individual patient needs. Prioritizing the inclusion of quality of life measures in future research should be a focus, ensuring these metrics are standard outcomes in clinical studies concerning third molar removals.

The primary limitation of this evidence mapping lies in its inability to analyze clinical and methodological heterogeneities among the trials included in the metaanalyses reviewed. These heterogeneities are critical for interpreting results, as they include differences in the characteristics of the third molars removed, variations in surgical procedures performed, the experience levels of the surgeons involved, and the use of medications in the pre- and post-operative phases. Such variations can significantly impact clinical outcomes and the efficacy of the interventions studied. The inability to detail and adjust for these clinical and methodological differences restricts the generalizability of the findings and may compromise the applicability of the clinical recommendations derived from this study. This issue underscores the need for more detailed and specific analyses that consider these critical variables in the planning of future research and in the formulation of evidence-based guidelines.

This evidence mapping revealed a predominantly low methodological quality among systematic reviews and meta-analyses that evaluated the effects of cryotherapy, surgical wound closure, and chlorhexidine following third molar surgery. Regarding the interventions:

1. Cryotherapy showed probable benefits in reducing pain and swelling on the second postoperative day. However, its effectiveness on other postoperative days and for reducing trismus remains unsupported by highquality evidence. These findings suggest that while cryotherapy may be beneficial shortly after surgery, its broader applications require more robust investigation.

2. Secondary closure was generally found to be beneficial or probably beneficial in reducing pain, swelling, and trismus during the first week post-surgery. However, high-quality evidence supports its benefit only in reducing pain on the first postoperative day and swelling after seven days. There is no substantial evidence supporting its effectiveness in reducing bleeding, infection, or alveolitis risk, highlighting the need for more high-quality research in these areas.

3. Chlorhexidine, particularly as a mouthwash, was consistently beneficial in preventing postoperative alveolitis. This suggests that chlorhexidine remains a valuable antiseptic tool in managing complications following third molar extractions.

In conclusion, while some interventions show potential benefits, the overall low quality of the evidence necessitates cautious interpretation of these results. Future research should prioritize improving methodological standards and expanding investigations into the patientcentered outcomes and the longitudinal effects of these interventions to better guide clinical practice.

## Acknowledgement

PRMF and FWGC are research productivity fellows at the National Council for Scientific and Technological Development (CNPq), Brazil.

#### Institutional Review Board Statement

Declared none.

#### Author Contributions

- Conception/design of the research: Edmundo Marques do Nascimento-Júnior, Paulo Ricardo Martins-Filho;

- Study selection: Edmundo Marques do Nascimento-Júnior, Paulo Ricardo Martins-Filho;

- Data collection: Edmundo Marques do Nascimento-Júnior, Paulo Ricardo Martins-Filho;

-Data analysis/interpretation: Edmundo Marques do Nascimento-Júnior, Fábio Wildson Gurgel Costa, Paulo Ricardo Martins-Filho;

- Supervision: Paulo Ricardo Martins-Filho, Fábio Wildson Gurgel Costa;

-Drafting the manuscript or making intellectual contributions on text/revisions: Edmundo Marques do Nascimento-Júnior, Fábio Wildson Gurgel Costa, Paulo Ricardo Martins-Filho;

-Final approval of the manuscript: Edmundo Marques do Nascimento-Júnior, Fábio Wildson Gurgel Costa, Paulo Ricardo Martins-Filho.

#### Funding

This study did not receive financial support.

#### **Conflict of interest**

The authors declare no conflict of interest, financial or otherwise.

## References

1. Duarte-Rodrigues L, Miranda EFP, Souza TO, de Paiva HN, Falci SGM, Galvão EL. Third molar removal and its impact on quality of life: Systematic review and meta-analysis. Qual Life Res. 2018;27:2477-89.

2. Shugars DA, Gentile MA, Ahmad N, Stavropoulos MF, Slade GD, Phillips C, *et al.* Assessment of oral health-related quality of life before and after third molar surgery. J Oral Maxillofac Surg. 2006;64:1721-30.

3. Cho H, Lynham A, Hsu E. Postoperative interventions to reduce inflammatory complications after third molar surgery: Review of the current evidence. Aust Dent J. 2017;62:412-9.

4. Malkawi Z, Al-Omiri MK, Khraisat A. Risk indicators of postoperative complications following surgical extraction of lower third molars. Med Prine Pract. 2011;20:321-5.

5. McGrath C, Comfort MB, Lo ECM, Luo Y. Changes in life quality following third molar surgery--the immediate postoperative period. Br Dent J. 2003;194:265-8.

6. Forouzanfar T, Sabelis A, Ausems S, Baart JA, Van-der-Waal I. Effect of ice compression on pain after mandibular third molar surgery: A single-blind, randomized controlled trial. Int J Oral Maxillofac Surg. 2008;37:824-30.

7. Bello SA, Olaitan AA, Ladeinde AL. A randomized comparison of the effect of partial and total wound closure techniques on postoperative morbidity after mandibular third molar surgery. J Oral Maxillofac Surg. 2011;69:e24-30.

8. Balamurugan R, Zachariah T. Comparison of primary and secondary closure with a buccal mucosal-advancement flap on postoperative course after mandibular impacted third molar surgery. Oral Maxillofac Surg. 2020;24:37-43.

9. Halabi D, Escobar J, Alvarado C, Martinez N, Muñoz C. Chlorhexidine for prevention of alveolar osteitis: A randomised clinical trial. J Appl Oral Sci. 2018;26:e20170245.

10. Torres-Lagares D, Gutierrez-Perez JL, Infante-Cossio P, Garcia-Calderon M, Romero-Ruiz MM, Serrera-Figallo MA. Randomized, double-blind study on effectiveness of intra-alveolar chlorhexidine gel in reducing the incidence of alveolar osteitis in mandibular third molar surgery. Int J Oral Maxillofac Surg. 2006;35:348-51.

11. Zandi M, Amini P, Keshavarz A. Effectiveness of cold therapy in reducing pain, trismus, and oedema after impacted mandibular third molar surgery: A randomized, self-controlled, observer-blind, split-mouth clinical trial. Int J Oral Maxillofac Surg. 2016;45:118-23. 12. Bragge P, Clavisi O, Turner T, Tavender E, Collie A, Gruen RL. The global evidence mapping initiative: Scoping research in broad topic areas. BMC Med Res Methodol. 2011;11:92.

15. Tricco AC, Lillie E, Zarin W, O'brien KK, Colquhoun H, Levac D, *et al.* PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169:467-73.

14. Anaya MM, Franco JVA, Ballesteros M, Solà I, Cuchí GU, Cosp XB. Evidence mapping and quality assessment of systematic reviews on therapeutic interventions for oral cancer. Cancer Manag Res. 2019;11:117-30.

15. Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, *et al.* AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

16. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ, *et al.* What is "quality of evidence" and why is it important to clinicians?. BMJ. 2008;336:995-8.

17. Fernandes IA, Armond ACV, Falci SGM. The effectiveness of the cold therapy (cryotherapy) in the management of inflammatory parameters after removal of mandibular third molars: A meta-analysis. Int Arch Otorhinolaryngol. 2019;23:221-8.

18. Nascimento-Júnior EM, Santos GMS, Mendes MLT, Cenci M, Correa MB, Cenci TP, *et al.* Cryotherapy in reducing pain, trismus, and facial swelling after third-molar surgery: Systematic review and meta-analysis of randomized clinical trials. J Am Dent Assoc. 2019;150:269-77.e1.

19. Azab M, Ibrahim S, Li A, Carrasco-Labra A, Zeng L, Brignardello-Petersen R, *et al.* Efficacy of secondary vs primary closure techniques for the prevention of postoperative complications after impacted mandibular third molar extractions: A systematic review update and meta-analysis. J Am Dent Assoc. 2022;153:943-56.e48.

20. Bailey E, Kashbour W, Shah N, Worthington HV, Renton TF, Coulthard P. Surgical techniques for the removal of mandibular wisdom teeth. Cochrane Database Syst Rev. 2020;7:CD004345.

21. Carrasco-Labra A, Brignardello-Petersen R, Yanine N, Araya I, Guyatt G. Secondary versus primary closure techniques for the prevention of postoperative complications following removal of impacted mandibular third molars: A systematic review and metaanalysis of randomized controlled trials. J Oral Maxillofac Surg. 2012;70:e441-57.

22. Ma S, Li X, Zhang A, Liu S, Zhao H, Zhao H. Efficacy of secondary closure technique after extraction of third molars: A metaanalysis. Br J Oral Maxillofac Surg. 2019;57:977-84.

23. Falci SGM, Guimarães MTBÁ, Canarim NM, Falci SE, Martins OBL, de Souza GM, *et al.* Comparison of suture and sutureless techniques on postoperative complications after third molar surgery: a systematic review. Clin Oral Investig. 2024;28:115.

24. Caso A, Hung LK, Beirne OR. Prevention of alveolar osteitis with chlorhexidine: A meta-analytic review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99:155-59.

25. Rodríguez Sánchez F, Rodríguez Andrés C, Arteagoitia Calvo I. Does chlorhexidine prevent alveolar osteitis after third molar extractions? Systematic review and meta-analysis. J Oral Maxillofac Surg. 2017;75:901-14.

26. Teshome A. The efficacy of chlorhexidine gel in the prevention of alveolar osteitis after mandibular third molar extraction: A systematic review and meta-analysis. BMC Oral Health. 2017;17:82.

27. Zhou J, Hu B, Liu Y, Yang Z, Song J. The efficacy of intra-alveo-

lar 0.2% chlorhexidine gel on alveolar osteitis: a meta-analysis. Oral Dis. 2017;23:598-608.

28. Daly BJM, Sharif MO, Jones K, Worthington H V., Beattie A. Local interventions for the management of alveolar osteitis (dry socket). Cochrane Database Syst Rev. 2022;9:CD006968.

29. Romero-Olid MN, Bucataru E, Ramos-García P, González-Moles MÁ. Efficacy of Chlorhexidine after Oral Surgery Procedures on Wound Healing: Systematic Review and Meta-Analysis. Antibiotics (Basel). 2023;12:1552

30. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, *et al.* Process evaluation of complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258

31. Ballesteros M, Montero N, López-Pousa A, Urrútia G, Solà I, Rada G, *et al.* Evidence mapping based on systematic reviews of therapeutic interventions for gastrointestinal stromal tumors (GIST). BMC Med Res Methodol. 2017;17:135.

32. Simmonds M. Quantifying the risk of error when interpreting funnel plots. Syst Rev. 2015;4:24.

33. Lyall JB. Third Molar Surgery: The Effect of Primary Closure, Wound Dressing and Metronidazole on Postoperative Recovery. J R Army Med Corps. 1991;137:100-3.

34. Menziletoglu D, Guler AY, Basturk F, Isik BK. Comparison of Surgical Drain Placement with Use of Kinesiologic Tape on Postoperative Pain, Swelling, and Trismus in Impacted Mandibular Third Molar Surgery. J Oral Maxillofac Surg. 2020;78:1919.e1-7.

35. Pachipulusu PK, S M. Comparative study of primary and secondary closure of the surgical wound after removal of impacted mandibular third molars. Oral Maxillofac Surg. 2018;22:261-6.

36. Fiorillo L. Chlorhexidine Gel Use in the Oral District: A Systematic Review. Gels. 2019;5:31.

37. Sanz M, Newman MG, Anderson L, Matoska W, Otomo-Corgel J, Saltini C. Clinical Enhancement of Post-Periodontal Surgical Therapy by a 0.12% Chlorhexidine Gluconate Mouthrinse. J Periodontol. 1989;60:570-6.

38. Hugo WB, Longworth AR. The effect of chlorhexidine on the electrophoretic mobility, cytoplasmic constituents, dehydrogenase activity and cell walls of Escherichia coli and Staphylococcus aureus. J Pharm Pharmacol. 2011;18:569-78.